Literature DB >> 2530069

Enzymic pathways of hyaluronan catabolism.

L Rodén1, P Campbell, J R Fraser, T C Laurent, H Pertoft, J N Thompson.   

Abstract

The enzymic degradation of hyaluronan in mammalian tissues takes place in two phases, encompassing breakdown of the polysaccharide to its monosaccharide constituents and subsequent utilization of the monosaccharide products. Degradation to the monosaccharide components is effected by the concerted action of three enzymes, hyaluronidase, beta-D-glucuronidase and beta-N-acetyl-D-hexosaminidase. The relative contributions of hyaluronidase and the two exoglycosidases to the physiological catabolism of hyaluronan are not yet known but consideration of the kinetic properties of the three enzymes clearly indicates that hyaluronidase is best suited for the initial attack on the polysaccharide, inasmuch as its Km for hyaluronan is 1000- to 10,000-fold lower than that estimated for beta-D-glucuronidase. Recent investigations in the authors' laboratories have been focused on the catabolism of hyaluronan and other complex carbohydrates in liver, since the sinusoidal endothelial cells in this organ are the main sites for degradation of circulating hyaluronan. Assay of ten lysosomal hydrolases in isolated rat liver cells showed considerably higher activities in Kupffer cells and endothelial cells than in hepatocytes for nine of the enzymes, including beta-D-glucuronidase and beta-N-acetyl-D-hexosaminidase. The activity of N-acetylglucosamine-6-phosphate deacetylase, a key enzyme in the metabolism of the N-acetylglucosamine released by the lysosomal degradation of hyaluronan and other complex carbohydrates, has also been determined. High deacetylase activities were observed in both Kupffer cells and endothelial cells but, surprisingly, virtually no activity was detected in hepatocytes. This finding implies that N-acetylglucosamine cannot be degraded in hepatocytes and must be largely reutilized in the synthesis of new macromolecules. Further studies of the enzymes involved in hyaluronan degradation and N-acetylglucosamine utilization in the liver are under way.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530069     DOI: 10.1002/9780470513774.ch5

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  16 in total

Review 1.  Scavenger functions of the liver endothelial cell.

Authors:  B Smedsrød; H Pertoft; S Gustafson; T C Laurent
Journal:  Biochem J       Date:  1990-03-01       Impact factor: 3.857

Review 2.  Endoglycosidases for the Synthesis of Polysaccharides and Glycoconjugates.

Authors:  Chao Li; Lai-Xi Wang
Journal:  Adv Carbohydr Chem Biochem       Date:  2016-08-23       Impact factor: 12.200

Review 3.  Immunologic roles of hyaluronan.

Authors:  Mark E Mummert
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Epidemiology of mucopolysaccharidoses.

Authors:  Shaukat A Khan; Hira Peracha; Diana Ballhausen; Alfred Wiesbauer; Marianne Rohrbach; Matthias Gautschi; Robert W Mason; Roberto Giugliani; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-05-26       Impact factor: 4.797

5.  Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX.

Authors:  B Triggs-Raine; T J Salo; H Zhang; B A Wicklow; M R Natowicz
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 6.  Hyaluronic acid in digestive cancers.

Authors:  Ruo-Lin Wu; Lei Huang; Hong-Chuan Zhao; Xiao-Ping Geng
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-17       Impact factor: 4.553

Review 7.  Biology of hyaluronan: Insights from genetic disorders of hyaluronan metabolism.

Authors:  Barbara Triggs-Raine; Marvin R Natowicz
Journal:  World J Biol Chem       Date:  2015-08-26

Review 8.  The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance.

Authors:  Eleni Papakonstantinou; George Karakiulakis
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

9.  Serum hyaluronidase aberrations in metabolic and morphogenetic disorders.

Authors:  Berta Fiszer-Szafarz; Barbara Czartoryska; Anna Tylki-Szymanska
Journal:  Glycoconj J       Date:  2005-11       Impact factor: 3.009

10.  Decreased lung hyaluronan in a model of ARDS in the rat: effect of an inhibitor of leukocyte elastase.

Authors:  Chul Min Ahn; Håkan Sandler; Tom Saldeen
Journal:  Ups J Med Sci       Date:  2012-01-27       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.